Skip to main content
. 2021 Jan 18;13(1):1850395. doi: 10.1080/19420862.2020.1850395

Figure 3.

Figure 3.

Characterization of chimeric GUCY2C T-BsAbs. (a) Top chimeric GUCY2C T-BsAb demonstrating CTL activity were scaled up and CTL activity against T84 tumor cells was repeated. These chimeric T-BsAbs were also analyzed for stability by DSC (b) and polyreactivity in both bispecific T-BsAb and monospecific anti-GUCY2C IgG format (c), as well as for binding to human CD3 and human GUCY2C recombinant protein by surface plasmon resonance (d)